We have a strong focus on investing in early-stage biotechnology companies that have the potential to transform the healthcare landscape. We believe that cell and gene therapies and regenerative medicines have the power to unlock new treatments and cures for a range of diseases, and we are passionate about supporting entrepreneurs who are working to make this a reality.
Our strategy is centered on identifying and combining innovative technologies and breakthrough science and partnering with visionary founders who have a deep understanding of their field. We build exciting ventures with pharma attractiveness and create value through our networks. Our goal is to help drive the growth of the biotech sector, and to create lasting value for our investors, our portfolio companies, and ultimately, for patients around the world.
Our approach combines Western expertise and Japanese innovation to build globally competitive companies that will have the greatest impact on patient lives.
People
- Jonathan Yeh, Managing Partner
You last contacted this investor on .